Investigational drug · Phase 3
[68Ga]Ga-DOTA-TATE
Also called: AAA501
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Extensive Stage Small Cell Lung Cancer, Neuroendocrine Neoplasms.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
n/a
Any phase or sponsor naming "[68Ga]Ga-DOTA-TATE"
First trial start
2022
Jul 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "[68Ga]Ga-DOTA-TATE", any sponsor or status.
Conditions studied
As listed on its trial records.
- Extensive Stage Small Cell Lung Cancer
- Neuroendocrine Neoplasms
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "[68Ga]Ga-DOTA-TATE" as an intervention, largest first.
- A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
NCT06240741 · Phase 3 · Completed · Novartis Pharmaceuticals · 71 participants · primary completion Dec 27, 2024
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696 · Phase 1/Phase 2 · Active, not recruiting · Novartis Pharmaceuticals · 55 participants · primary completion Mar 7, 2028
Newest research
PubMed records naming it or its code names, newest first.
- When an SSTR-negative lesion does not preclude RLT: the role of dual-tracer PET/CT in a neuroendocrine tumor.
Jóźwik-Plebanek K, Saracyn M, Midra W, et al. · Endokrynol Pol 2026
- Head-to-Head Comparison of [ 18 F]MFBG and [ 68 Ga]Ga-DOTA-TATE PET/CT in Suspected Recurrent/Refractory Neuroblastoma: Prospective Single-center Analysis.
Xu Q, Chen Y, Song J, et al. · Clin Nucl Med 2026
- Superior vena cava syndrome as a manifestation of primary atypical carcinoid tumor of mediastinum by [68Ga]Ga-DOTA-TATE PET/CT.
Daşar M, Akbulut A, Özdemir S, et al. · Rev Esp Med Nucl Imagen Mol (Engl Ed) 2026
- Evaluation of ultrasonographic and clinicopathological features of patients with abnormal [68Ga]Ga-DOTA-TATE uptake in the thyroid gland.
Turan Erdogan B, Dellal Kahramanca FD, Karaahmetli G, et al. · EJNMMI Res 2026
- Head-to-Head comparison of [18F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors: a prospective study.
Liu H, Ma G, Wen H, et al. · Eur J Nucl Med Mol Imaging 2026
- [177Lu]Lu-DOTA-TATE tumour and organ time-activity curves: prediction from a single-time-point [68Ga]Ga-DOTA-TATE PET/CT measurement.
Vasik V, Gustafsson J, Yousefzadeh-Nowshahr E, et al. · EJNMMI Phys 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.